ARCH Venture Partners Overview
A venture firm specializing in early-stage investments aimed at life science innovations to prevent, detect, and cure diseases.
Latest News
growth-positive
Arch raises another $3B biotech fund in pursuit of ‘coolest’ new science
Arch Venture Partners has successfully raised over $3 billion for its 13th fund, continuing its strategy of investing in cutting-edge biotechnology startups. The firm, known for its focus on high-powered computing tools and artificial intelligence in drug discovery, remains a key player in the biotech sector despite challenging market conditions. Archs recent investments include a $1 billion funding round for Xaira Therapeutics, an AI-driven biotech startup. The firm emphasizes early-stage investments and ensuring strong leadership in its portfolio companies. Other notable biotech venture firms raising funds this year include Foresite Capital, Flagship Pioneering, Sands Capital, and Scion Life Sciences.
Investment
Growth-Positive
ARCH Venture Partners is raising $3 billion for a life sciences fund
ARCH Venture Partners, a leading investor in the biotech ecosystem, is planning to raise $3 billion for its 13th fund. The Chicago-based firm has filed the necessary paperwork with the Securities and Exchange Commission. The amount they aim to raise is similar to what they raised in their most recent fundraising in 2022.
Investment
Team Members
0
Web & Social Links
Locations
Chicago, IL, USA
Photos & Videos
No files yet
ARCH Venture Partners Business
Business models
—
Product stage
—
Employees
—
Sector
—Target Customer
—Core Technology
—Tags (2)
life-sciencesbiotechnologyARCH Venture Partners Financials
—
Total funding
—
Capital raised
—
Last funding
—
Funding stage
—
Total rounds
—
Investors
ARCH Venture Partners Lifecycle
ARCH Venture Partners News
2 articles
growth-positive
Arch raises another $3B biotech fund in pursuit of ‘coolest’ new science
Arch Venture Partners has successfully raised over $3 billion for its 13th fund, continuing its strategy of investing in cutting-edge biotechnology startups. The firm, known for its focus on high-powered computing tools and artificial intelligence in drug discovery, remains a key player in the biotech sector despite challenging market conditions. Archs recent investments include a $1 billion funding round for Xaira Therapeutics, an AI-driven biotech startup. The firm emphasizes early-stage investments and ensuring strong leadership in its portfolio companies. Other notable biotech venture firms raising funds this year include Foresite Capital, Flagship Pioneering, Sands Capital, and Scion Life Sciences.
Investment
Growth-Positive
ARCH Venture Partners is raising $3 billion for a life sciences fund
ARCH Venture Partners, a leading investor in the biotech ecosystem, is planning to raise $3 billion for its 13th fund. The Chicago-based firm has filed the necessary paperwork with the Securities and Exchange Commission. The amount they aim to raise is similar to what they raised in their most recent fundraising in 2022.
Investment
ARCH Venture Partners Team
No team members listed.
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
ARCH Venture Partners Internal
Recent Updates
Ortal Wein
· ortalw@sncentral.org · Manual · 2024-10-06 11:14:13.000000
Ortal Wein
· ortalw@sncentral.org · Automatic · 2024-10-06 11:14:13.000000
Ortal Wein
· ortalw@sncentral.org · Manual · 2024-10-06 11:14:12.000000
Ortal Wein
· ortalw@sncentral.org · Automatic · 2024-10-06 11:14:12.000000
Ortal Wein
· ortalw@sncentral.org · Manual · 2024-10-06 11:14:12.000000
Ortal Wein
· ortalw@sncentral.org · Manual · 2024-10-06 11:14:12.000000
Ortal Wein
· ortalw@sncentral.org · Manual · 2024-10-06 11:14:12.000000
Ortal Wein
· ortalw@sncentral.org · Automatic · 2024-10-06 11:14:12.000000
Ortal Wein
· ortalw@sncentral.org · Manual · 2024-10-06 11:14:12.000000
Ortal Wein
· ortalw@sncentral.org · Automatic · 2024-10-06 11:14:13.000000
Ortal Wein
· ortalw@sncentral.org · Manual · 2024-02-04 07:18:42.000000
Ortal Wein
· ortalw@sncentral.org · Manual · 2024-10-06 11:14:13.000000
Ortal Wein
· ortalw@sncentral.org · Manual · 2024-10-06 11:14:12.000000
Ortal Wein
· ortalw@sncentral.org · Automatic · 2024-10-06 11:14:12.000000
Ortal Wein
· ortalw@sncentral.org · Manual · 2024-10-06 11:14:12.000000
Ortal Wein
· ortalw@sncentral.org · Manual · 2024-10-06 11:14:12.000000
Ortal Wein
· ortalw@sncentral.org · Manual · 2024-10-06 11:14:12.000000
Ortal Wein
· ortalw@sncentral.org · Manual · 2024-10-06 11:14:12.000000
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 25/100 |
| Missing | product stage, sector, number of employees, tags, invite member, business model, tag line, description, homepage, video or image, funding rounds, markets, external profiles, not claimed |
| Creator | RPA |
| Creator email | sncentraltest@gmail.com |
| Last update | 2022-06-14T00:00:00.000Z |
| Created | 2019-05-11T00:00:00.000Z |
| Status detail | Active |